M&A · Healthcare · Pharmaceutical Preparations
Concentra Biosciences, LLC to acquire Kronos Bio, Inc.
Announced May 1, 2025 · Closed Jun 20, 2025
Deal value$35M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$0.57 per share
Transaction
- Acquirer
- Concentra Biosciences, LLC
- Target
- Kronos Bio, Inc. (KRON)
- Buyer type
- Private equity
- Offer price per share
- $0.57
- Enterprise value
- —
- Status
- Closed Jun 20, 2025
Deal protections
- Break fee (target pays)
- $1.4M · 4.0%
- Reverse fee (buyer pays)
- —
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 92 in the prior 24 months
- Premium
- Sector median 66.5%
- EV / Adj. EBITDA
- Sector median 13.8x
- Break fee
- 4.0% vs. 3.4% sector median
Timeline
- AnnouncedMay 1, 2025
- Tender offerMay 15, 2025
- ClosedJun 20, 2025